• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双膦酸衍生物的结构与功能的新认识及其对 CFTR 调节的影响。

New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation.

机构信息

INSERM U1151, Institut Necker Enfants Malades, Université de Paris, 75015, Paris, France.

Muséum National d'Histoire Naturelle, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université, 75005, Paris, France.

出版信息

Sci Rep. 2021 Mar 25;11(1):6842. doi: 10.1038/s41598-021-83240-x.

DOI:10.1038/s41598-021-83240-x
PMID:33767236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7994384/
Abstract

C407 is a compound that corrects the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein carrying the p.Phe508del (F508del) mutation. We investigated the corrector effect of c407 and its derivatives on F508del-CFTR protein. Molecular docking and dynamics simulations combined with site-directed mutagenesis suggested that c407 stabilizes the F508del-Nucleotide Binding Domain 1 (NBD1) during the co-translational folding process by occupying the position of the p.Phe1068 side chain located at the fourth intracellular loop (ICL4). After CFTR domains assembly, c407 occupies the position of the missing p.Phe508 side chain. C407 alone or in combination with the F508del-CFTR corrector VX-809, increased CFTR activity in cell lines but not in primary respiratory cells carrying the F508del mutation. A structure-based approach resulted in the synthesis of an extended c407 analog G1, designed to improve the interaction with ICL4. G1 significantly increased CFTR activity and response to VX-809 in primary nasal cells of F508del homozygous patients. Our data demonstrate that in-silico optimized c407 derivative G1 acts by a mechanism different from the reference VX-809 corrector and provide insights into its possible molecular mode of action. These results pave the way for novel strategies aiming to optimize the flawed ICL4-NBD1 interface.

摘要

C407 是一种能校正囊性纤维化跨膜电导调节因子(CFTR)蛋白携带 p.Phe508del(F508del)突变的化合物。我们研究了 C407 及其衍生物对 F508del-CFTR 蛋白的校正作用。分子对接和动力学模拟结合定点突变表明,C407 通过占据位于第四细胞内环(ICL4)的 p.Phe1068 侧链的位置,在共翻译折叠过程中稳定 F508del-Nucleotide Binding Domain 1(NBD1)。在 CFTR 结构域组装后,C407 占据缺失的 p.Phe508 侧链的位置。C407 单独或与 F508del-CFTR 校正剂 VX-809 联合使用,可增加细胞系中的 CFTR 活性,但不能增加携带 F508del 突变的原代呼吸细胞中的 CFTR 活性。基于结构的方法导致合成了一个扩展的 C407 类似物 G1,旨在改善与 ICL4 的相互作用。G1 显著增加了 F508del 纯合患者原代鼻细胞中的 CFTR 活性和对 VX-809 的反应。我们的数据表明,经计算机优化的 C407 衍生物 G1 通过与参考校正剂 VX-809 不同的机制发挥作用,并为其可能的分子作用模式提供了见解。这些结果为旨在优化有缺陷的 ICL4-NBD1 界面的新策略铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/24423c1957c1/41598_2021_83240_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/4ffa1f049b37/41598_2021_83240_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/b151025f1079/41598_2021_83240_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/fbc1c1ad30dd/41598_2021_83240_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/bd99deb7c240/41598_2021_83240_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/ddf814b96ab7/41598_2021_83240_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/24423c1957c1/41598_2021_83240_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/4ffa1f049b37/41598_2021_83240_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/b151025f1079/41598_2021_83240_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/fbc1c1ad30dd/41598_2021_83240_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/bd99deb7c240/41598_2021_83240_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/ddf814b96ab7/41598_2021_83240_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/7994384/24423c1957c1/41598_2021_83240_Fig6_HTML.jpg

相似文献

1
New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation.双膦酸衍生物的结构与功能的新认识及其对 CFTR 调节的影响。
Sci Rep. 2021 Mar 25;11(1):6842. doi: 10.1038/s41598-021-83240-x.
2
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.三药复方(Trikafta)依利卓艾他康唑/艾美拉唑/卡博替尼(elexacaftor-tezacaftor-ivacaftor)对 F508del 及罕见 CFTR 突变体的别构折叠校正。
JCI Insight. 2020 Sep 17;5(18):139983. doi: 10.1172/jci.insight.139983.
3
Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.RDR01752 作用机制的表征:一种新型 F508del-CFTR 校正剂。
Biochem Pharmacol. 2020 Oct;180:114133. doi: 10.1016/j.bcp.2020.114133. Epub 2020 Jul 3.
4
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.VX-809 通过作用于跨膜域 1 纠正囊性纤维化跨膜电导调节蛋白的折叠缺陷。
Mol Biol Cell. 2013 Oct;24(19):3016-24. doi: 10.1091/mbc.E13-05-0240. Epub 2013 Aug 7.
5
Systemic bis-phosphinic acid derivative restores chloride transport in Cystic Fibrosis mice.系统双膦酸衍生物可恢复囊性纤维化小鼠的氯离子转运。
Sci Rep. 2022 Apr 12;12(1):6132. doi: 10.1038/s41598-022-09678-9.
6
Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.药理学伴侣通过不同的结合位点改善域内稳定性和域间组装,以拯救错误折叠的 CFTR。
Cell Mol Life Sci. 2021 Dec;78(23):7813-7829. doi: 10.1007/s00018-021-03994-5. Epub 2021 Oct 29.
7
Can two wrongs make a right? F508del-CFTR ion channel rescue by second-site mutations in its transmembrane domains.两个错误能否变成正确的?第二跨膜区突变对 F508del-CFTR 离子通道的拯救作用。
J Biol Chem. 2022 Mar;298(3):101615. doi: 10.1016/j.jbc.2022.101615. Epub 2022 Jan 21.
8
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.一项研究 VX-809(一种研究用的 CFTR 校正化合物)的 IIa 期临床研究结果,该化合物用于 F508del-CFTR 突变纯合子的囊性纤维化患者。
Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.
9
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.双校正剂治疗部分挽救 F508del-CFTR 的稳定性和运输缺陷。
Int J Mol Sci. 2021 May 17;22(10):5262. doi: 10.3390/ijms22105262.
10
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.通过研究药物 VX-809 纠正体外 F508del-CFTR 蛋白加工缺陷。
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8. doi: 10.1073/pnas.1105787108. Epub 2011 Oct 5.

引用本文的文献

1
Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review.囊性纤维化跨膜传导调节因子调节剂的作用机制、结合位点及治疗进展解析:一篇综述
Curr Issues Mol Biol. 2025 Feb 11;47(2):119. doi: 10.3390/cimb47020119.
2
ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches.ATP结合盒转运体与溶质载体转运体:通过结构和建模方法理解其机制及药物调控
Pharmaceuticals (Basel). 2024 Nov 27;17(12):1602. doi: 10.3390/ph17121602.
3
Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.

本文引用的文献

1
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
2
Molecular structure of the ATP-bound, phosphorylated human CFTR.ATP 结合磷酸化的人 CFTR 的分子结构。
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12757-12762. doi: 10.1073/pnas.1815287115. Epub 2018 Nov 20.
3
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
计算探索 I 型校正药物潜在的 CFTR 结合位点。
Biochemistry. 2023 Aug 15;62(16):2503-2515. doi: 10.1021/acs.biochem.3c00165. Epub 2023 Jul 12.
4
Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing.虚拟药物重定位鉴定与 Lumacaftor 协同作用的天然小分子,以增强 F508del-CFTR 结合和恢复功能。
Int J Mol Sci. 2022 Oct 14;23(20):12274. doi: 10.3390/ijms232012274.
5
One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.一概而论:囊性纤维化因果治疗的过去、现在和未来。
Cells. 2022 Jun 8;11(12):1868. doi: 10.3390/cells11121868.
6
An Update on CFTR Drug Discovery: Opportunities and Challenges.囊性纤维化跨膜传导调节因子(CFTR)药物研发的最新进展:机遇与挑战。
Biomolecules. 2022 Jun 6;12(6):792. doi: 10.3390/biom12060792.
7
Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy.囊性纤维化的分子机制——突变如何导致功能障碍及指导治疗。
Biosci Rep. 2022 Jul 29;42(7). doi: 10.1042/BSR20212006.
8
Systemic bis-phosphinic acid derivative restores chloride transport in Cystic Fibrosis mice.系统双膦酸衍生物可恢复囊性纤维化小鼠的氯离子转运。
Sci Rep. 2022 Apr 12;12(1):6132. doi: 10.1038/s41598-022-09678-9.
VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
4
Structure-guided combination therapy to potently improve the function of mutant CFTRs.结构导向的联合治疗可显著改善突变型 CFTR 的功能。
Nat Med. 2018 Nov;24(11):1732-1742. doi: 10.1038/s41591-018-0200-x. Epub 2018 Oct 8.
5
Combining theoretical and experimental data to decipher CFTR 3D structures and functions.结合理论和实验数据来破解 CFTR 的三维结构和功能。
Cell Mol Life Sci. 2018 Oct;75(20):3829-3855. doi: 10.1007/s00018-018-2835-7. Epub 2018 May 19.
6
Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.主要囊性纤维化突变体的校正因子通过跨膜结构域相互作用。
Mol Pharmacol. 2018 Jun;93(6):612-618. doi: 10.1124/mol.118.111799. Epub 2018 Apr 4.
7
Holding the Nucleosome Together: A Quantitative Description of the DNA-Histone Interface in Solution.维持核小体的结构:溶液中DNA-组蛋白界面的定量描述
J Chem Theory Comput. 2018 Feb 13;14(2):1045-1058. doi: 10.1021/acs.jctc.7b00936. Epub 2018 Jan 8.
8
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators.囊性纤维化患者鼻黏膜上皮细胞中 CFTR 功能的校正可预测 CFTR 调节剂对呼吸功能的改善。
Sci Rep. 2017 Aug 7;7(1):7375. doi: 10.1038/s41598-017-07504-1.
9
Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface.校正剂VX-809与人囊性纤维化跨膜传导调节因子核苷酸结合结构域1的直接结合:结合位点与核苷酸结合结构域1:CL4界面之间变构偶联的证据
Mol Pharmacol. 2017 Aug;92(2):124-135. doi: 10.1124/mol.117.108373. Epub 2017 May 25.
10
Cystic fibrosis.囊性纤维化。
Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29.